Showing 5061-5070 of 7584 results for "".
- AAD Responds to New York Timeshttps://practicaldermatology.com/news/20140127-aad_sumbits_letter_to_the_editor_to_new_york_times/2459358/In response to The New York Times article “Patients' Costs Skyrocket; Specialists' Incomes Soar” (“Paying Till It Hurts” series, Jan. 19, 2014), the American Academy of De
- DERM: The Dermatology Essential Resource Meeting Announcedhttps://practicaldermatology.com/news/20140122-derm_the_dermatology_essential_resource_meeting_announced/2459364/DERM 2014: The Dermatology Essential Resource Meeting will be held July 24-27 at the Encore in Las Vegas. This new, accredited conference focuses exclusively on clinically relevant and practical educational needs of NPs and PAs in dermatology, according t
- Anti-Aging Technology Using the “Science of Heat” to be Presented at AACShttps://practicaldermatology.com/news/20140117-anti-aging_technology_using_the_science_of_heat_to_be_presented_at_aacs/2459368/An anti-aging technology that uses the “science of heat” will be presented tomorrow at the American Academy of Cosmetic Surgery (AACS) 30th Annual Scientific Meeting in Fort Lauderdale, FL. ThermiRF is a minimally invasive method of tightening sagging skin and reducing the appearance of fine lines a
- Injectable Methotrexate Product Now Availablehttps://practicaldermatology.com/news/20140117-injectable_methotrexate_product_now_available/2459369/For patients who do not tolerate oral methotrexate for psoriasis, a new recently approved injectable methotrexate product is now available from Antares Pharma. Approved in October 2013 for the subcutaneous methotrexate product for once weekly self-administration, Otrexup is indicated for use in adul
- Alma Lasers Debuts its 2014 Webinar Serieshttps://practicaldermatology.com/news/20140116-alma_lasers_debuts_its_2014_webinar_series/2459372/In a complimentary webinar series, industry experts will showcase their success building local market awareness to drive practice results. Spearheaded by Alma Lasers , the informative ses
- Caliber Imaging & Diagnostics Receives $1.4 Million Order for VivaScope® Systems From European Distributor MAVIG GmbHhttps://practicaldermatology.com/news/20140114-caliber_imaging__diagnostics_receives_14_million_order_for_vivascope_systems_from_european_distributor_mavig_gmbh/2459373/Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., announces receipt of $1.4 million in orders for VivaScope® systems from its European distributor MAVIG GmbH. These units are scheduled to be shipped in the first half of 2014. MAVIG has been Caliber's exclusive distributor in Europe f
- Daniel Siegel, MD Appointed to Board of Directors for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140113-daniel_siegel_md_appointed_to_cabilber_imaging__diagnostics_board_of_directors/2459374/Caliber Imaging & Diagnostics, formerly Lucid, Inc., appointed Daniel Mark Siegel, MD to its Board of Directors, effective immediately. This increases the number of Board members to eight. Dr. Siegel is Clinical Professor of Dermatology at SUNY Downstate Medical Center (State Univ
- FDA Approves Combination Use of GSK's Mekinist® (trametinib) and Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140109-fda_approves_combination_use_of_gsks_mekinist_trametinib_and_tafinlar_dabrafenib/2459375/GlaxoSmithKline plc [LSE/NYSE: GSK] has received FDA approval of Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutation
- KYTHERA Biopharmaceuticals to Present at 32nd Annual J.P. Morgan Healthcare Conferencehttps://practicaldermatology.com/news/20140107-kythera_biopharmaceuticals_to_present_at_32nd_annual_jp_morgan_healthcare_conference/2459378/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
- Suneva Medical Announces 12-Month Safety Results From Artefill® Acne Scar Studyhttps://practicaldermatology.com/news/20140107-suneva_medical_announces_12-month_safety_results_from_artefill_acne_scar_study/2459379/Suneva Medical Inc. announced the 12-month follow-up data from its randomized, double-blinded, multi-center, Pivotal acne scar investigational study evaluating the safety and efficacy of ArteFillâ, a dermal filler, to treat acne scars.